



08-19-03

1614

PTO/SB/USA

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et
Group Art Unit	1614
Examiner Name	Unknown

AUG 2 3 2003  
TECH CENTER 1601/2800

RECEIVED

Sheet	1	of	13	Attorney Docket No.	PHA 4297 (3167/8Z)
-------	---	----	----	---------------------	--------------------

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1.	4,100,274		Dutta et al.	07-11-1978
	2.	4,105,681		Bollag et al.	08-08-1978
	3.	4,140,707		Cleare et al.	02-20-1979
	4.	4,215,215		Bollag et al.	07-29-1980
	5.	5,250,683		Holton et al.	10-05-1993
	6.	5,254,703		Holton	10-19-1993
	7.	5,272,171		Ueda et al.	12-21-1993
	8.	5,319,112		Kingston et al.	06-07-1994
	9.	5,344,991		Reitz et al.	09-06-1994
	10.	5,455,270		Kaplan et al.	10-03-1995
	11.	5,633,016		Johnson	05-27-1997
	12.	5,686,419		Powers et al.	11-11-1997
	13.	5,696,131		Baguley et al.	12-09-1997
	14.	5,733,909		Black et al.	03-31-1998
	15.	5,767,142		LaVoie et al.	06-16-1998
	16.	5,824,699		Kreft et al.	10-20-1998

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUG 18 2003

1000

PATO/SB/08  
PATENT & TRADEMARK OFFICE

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket No.	PHA 4297 (3167/8Z)

Sheet 2 of 13

RECEIVED  
AUG 23 2003  
TECH CENTER 160012900

17.	5,837,696		Golub et al.	11-17-1998
18.	5,869,524		Failli	02-09-1999
19.	5,952,381		Chen et al.	09-14-1999

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
	20.	DE	195 48 798	A1	Dr. Karl Thomae GmbH	07-03-1997	A
	21.	DE	196 13 933	A1	Merck Patent GmbH	10-09-1997	A
	22.	DE	196 26 701	A1	Hoechst AG	01-08-1998	A
	23.	EP	0 010 458	A1	ANVAR	04-30-1980	A
	24.	EP	0 054 168	A1	Klinge Pharma GmbH & Co.	06-23-1982	A
	25.	EP	0 095 875	A2	Farmos Group Ltd.	12-07-1983	
	26.	EP	0 165 904	A2	Ciba-Geigy AG	12-27-1985	A
	27.	EP	0 199 636	A1	C.I.R.D.	10-29-1986	A
	28.	EP	0 236 940	B1	Ciba-Geigy AG	09-16-1987	
	29.	EP	0 260 744	B1	Janssen Pharmaceutica N.V.	03-23-1988	
	30.	EP	0 299 402	A2	ASTA Pharma Aktiengesellschaft	01-18-1989	A
	31.	EP	0 331 983	A2	F. Hoffmann-La Roche AG	09-13-1989	A
	32.	EP	0 402 232	A1	Rhone-Poulenc Sante	12-12-1990	A

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUG 18 2003

PTO/SB/05A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket No.	PHA 4297 (3167/8Z)

Sheet

3

of

13

33.	EP	0 532 156	A1	Matsuno et al.	03-17-1993	
34.	EP	0 579 915	A1	F. Hoffmann-La Roche AG	01-26-1994	A
35.	EP	0 702 962	A2	Eli Lilly and Company	03-27-1996	
36.	EP	0 703 239	A1	Hoechst Aktiengesellschaft	03-27-1996	A
37.	EP	0 743 070	A2	Trnka Mudr et al.	11-20-1996	A
38.	EP	0 921 119	A1	ADIR Et Compagnie	06-09-1999	A
39.	WO	87/07609	A1	Taiho Pharmaceutical Co., Ltd.	12-17-1987	A
40.	WO	93/11145	A1	Banyu Pharmaceutical Co., Ltd.	06-10-1993	
41.	WO	93/18652	A1	Merck & Co.	09-30-1993	
42.	WO	93/20229	A1	Genentech, Inc.	10-14-1993	
43.	WO	94/02466	A1	The Du Pont Merck Pharmaceutical Company	02-03-1994	
44.	WO	94/12169	A1	Merck & Co., Inc.	06-09-1994	
45.	WO	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994	
46.	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994	
47.	WO	94/25431	A1	The Wellcome Foundation Limited	11-10-1994	
48.	WO	94/25466	A1	Glaxo, Inc.	11-10-1994	
49.	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994	
50.	WO	94/27980	A1	G.D. Searle & Co.	12-08-1994	
51.	WO	95/02603	A2	Pharmacia S.P.A.	01-26-1995	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
AUG 20 2003  
TECH CENTER 1600/2900

AUG 18 2003

JCSO  
PATENT & TRADEMARK OFFICE

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Compleat if Known**

Application Number	09/868,261
Filing Date	October 5, 200
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket No.	PHA 4297 (3167/8Z)

Sheet	4	of	13
-------	---	----	----

52.	WO	95/08327	A1	The Government of the United States of America	03-30-1995
53.	WO	95/11883	A1	G.D. Searle & Co.	05-04-1995
54.	WO	95/12606	A1	The Wellcome Foundation Limited	05-11-1995
55.	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995
56.	WO	95/24199	A2	Cell Therapeutics, Inc.	09-14-1995
57.	WO	95/28426	A2	La Jolla Cancer Research Foundation	10-26-1995
58.	WO	95/30652	A1	G.D. Searle & Co.	11-16-1995
59.	WO	95/30656	A1	G.D. Searle & Co.	11-16-1995
60.	WO	96/00574	A1	Smithkline Beecham Corporation	01-11-1996
61.	WO	96/00581	A1	Texas Biotechnology Corporation	01-11-1996
62.	WO	96/01653	A1	Board of Regents, The University of Texas System et al.	01-25-1996
63.	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996
64.	WO	96/03392	A1	G.D. Searle & Co.	02-08-1996
65.	WO	96/06840	A1	Merck Frosst Canada Inc.	03-07-1996
66.	WO	96/14745	A1	The Regents of the University of California	05-23-1996
67.	WO	96/21667	A1	Merck Frosst Canada Inc.	07-18-1996
68.	WO	96/33988	A1	Wisconsin Alumni Research Foundation	10-31-1996

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
AUG 23 2003  
TECH CENTER 1601/2900

AUG 18 2003

3C860

PATENT &amp; TRADEMARK OFFICE

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket No.	PHA 4297 (3167/8Z)

Sheet

5

of

13

RECEIVED  
AUG 23 2003  
TECH CENTER 160012900

69.	WO	96/35774	A2	The Children's Medical Center Corporation	11-14-1996	
70.	WO	96/36335	A1	Pharmacia S.P.A.	11-21-1996	
71.	WO	96/36612	A1	Rutgers, The State University of New Jersey	11-21-1996	
72.	WO	96/36622	A1	Indena S.P.A.	11-21-1996	
73.	WO	96/36623	A1	Merck Frosst Canada Inc.	11-21-1996	
74.	WO	96/37469	A1	Merck Frosst Canada Inc.	11-28-1996	
75.	WO	97/08145	A1	G.D. Searle & Co.	03-06-1997	
76.	WO	97/11718	A1	The Victoria University of Manchester	04-03-1997	
77.	WO	97/15666	A1	The Children's Medical Center Corporation	05-01-1997	
78.	WO	97/15676	A2	Abbott Laboratories	05-01-1997	
79.	WO	97/19954	A1	Asta Medica Aktiengesellschaft	06-05-1997	
80.	WO	97/20835	A1	Harbor Branch Oceanographic Institution, Inc.	06-12-1997	
81.	WO	97/23451	A1	Merck Patent Gesellschaft Mit Beschränkter Haftung	07-03-1997	A
82.	WO	97/23480	A1	The Du Pont Merck Pharmaceutical Company	07-03-1997	
83.	WO	97/24116	A2	Allergan	07-10-1997	
84.	WO	97/29106	A1	Rutgers, The State University of New Jersey	08-14-1997	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUG 18 2003

3060

P.O./SB/08

PATENT &amp; TRADEMARK OFFICE

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown

Sheet	6	of	13	Attorney Docket No.	PHA 4297 (3167/8Z)
-------	---	----	----	---------------------	--------------------

	85.	WO	97/31936	A2	Wisconsin Alumni Research Foundation	09-04-1997	
	86.	WO	97/33887	A1	The Du Pont Merck Pharmaceutical Company	09-18-1997	
	87.	WO	97/34608	A1	Mayo Foundation for Medical Education and Research	09-25-1997	
	88.	WO	97/36497	A2	Mars, Incorporated	10-09-1997	
	89.	WO	97/36860	A1	G.D. Searle & Co.	10-09-1997	
	90.	WO	97/36863	A1	Merck Frosst Canada Inc.	10-09-1997	
	91.	WO	97/37658	A1	Boehringer Mannheim Italia S.P.A.	10-16-1997	
	92.	WO	97/41844	A1	Alcon Laboratories, Inc.	11-13-1997	
	93.	WO	97/47296	A2	Mount Sinai Hospital Corporation	12-18-1997	
	94.	WO	97/49704	A1	Janssen Pharmaceutica N.V.	12-31-1997	
	95.	WO	98/03484	A1	Merck Frosst Canada Inc.	01-29-1998	
	96.	WO	98/07432	A1	American Home Products Corporation	02-26-1998	
	97.	WO	98/07433	A1	Bristol-Myers Squibb Company	02-26-1998	
	98.	WO	98/12181	A1	Rutgers, The State University of New Jersey	03-26-1998	
	99.	WO	98/13350	A1	Zeneca Limited	04-02-1998	
	100.	WO	98/14188	A1	Ilex Oncology Inc.	04-09-1998	
	101.	WO	98/16227	A1	G.D. Searle & Co.	04-23-1998	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
AUG 20 2003  
TECH CENTER 1900128008

AUG 18 2003

PATO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown

Sheet	7	of	13	Attorney Docket No.	PHA 4297 (3167/8Z)
-------	---	----	----	---------------------	--------------------

102.	WO	98/22101	A2	G.D. Searle & Co.	05-28-1998
103.	WO	98/25603	A1	Ilex Oncology, Inc.	06-18-1998
104.	WO	98/25896	A1	G.D. Searle & Co.	06-18-1998
105.	WO	98/40104	A2	Yale University et al.	09-17-1998
106.	WO	98/45294	A1	Astra Pharmaceuticals Ltd.	10-15-1998
107.	WO	99/01131	A1	Smithkline Beecham Corporation	01-14-1999
108.	WO	99/05104	A1	Pfizer Pharmaceuticals Inc.	02-04-1999
109.	WO	99/10331	A1	Abbott Laboratories	03-04-1999
110.	WO	99/12930	A1	Glaxo Group Limited	03-18-1999
111.	WO	99/14194	A1	Merck Frosst Canada Inc.	03-25-1999
112.	WO	99/14205	A1	Almirall Prodesfarma S.A.	03-25-1999
113.	WO	99/21583	A1	Warner-Lambert Company	05-06-1999
114.	WO	99/23087	A1	Merck Frosst Canada & Co.	05-14-1999
115.	WO	99/31067	A1	Rutgers, The State University of New Jersey	06-24-1999
116.	WO	99/41241	A1	Rutgers, The State University of New Jersey	08-19-1999

**OTHER ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
--------------------	-----------------------	--	----------------

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUG 18 2003

PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown

Sheet	8	of	13	Attorney Docket No.	PHA 4297 (3167/8Z)
-------	---	----	----	---------------------	--------------------

117.	BARNI, S., et al., Clinical Efficacy of the Aromatase Inhibitor Anastrozole in Relation to Prolactin Secretion in Heavily Pretreated Metastatic Breast Cancer, Tumouri, Jan.-Feb. 1998, pp. 45-47, Vol. 84(1)
118.	BENSON, J.R., et al., Tamoxifen, Biologic Therapy of Cancer: Principles and Practice, 1997, pp. 817-828, Vol. One, Ch. 29, J.F. Holland et al. (Eds.), Baltimore, MD
119.	BREMBECK, F.H., et al., A Phase II Pilot Trial of 13-cis Retinoic Acid and Interferon- $\alpha$ in UICC Stage III/IV Pancreatic Cancer, Gastroenterology Oncology, April 1998, Abstract G2329, Vol. 114, No. 4, Pt. 2, A569
120.	BREMBECK, F.H., et al., A Phase II Trial of 13-cis Retinoic Acid and Interferon- $\alpha$ in Patients with Advanced Pancreatic Carcinoma, Cancer, 1998, pp. 2317-2323, Vol. 83, No. 11
121.	BROOKS, P.C., et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, Cell, Dec. 30, 1994, pp. 1157-1164, Vol. 79
122.	BROWN, F.K., et al., Matrix Metalloproteinase Inhibitors Containing a (Carboxyalkyl)amino Zinc Ligand: Modification of the P1 and P2' Residues, J. Med. Chem., 1994, pp. 674-688, Vol. 37
123.	CAO, Y., et al., Kringle Domains of Human Angiostatin, The Journal of Biological Chemistry, Nov. 15, 1996, pp. 29461-29467, Vol. 271, No. 46
124.	DONG, Z, et al., Macrophage-Derived Metalloelastase is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma, Cell, Mar. 21, 1997, pp. 801-810, Vol. 88
125.	DRUMMOND, A.H., et al., Preclinical and Clinical Studies of MMP Inhibitors in Cancer, Annals of the New York Academy of Science, June 1999, pp. 228-235, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)
126.	DURANDO, A., et al., Combination chemotherapy with paclitaxel (T) and epirubicin (E) for metastatic breast cancer (MBC): A phase I-II study, European Journal of Cancer, Sept. 30, 1998, pp. S12-13, Abstract 41
127.	FAN, T.-P.D., et al., Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy, Trends Pharmacol.Sci. Feb. 1995, pp. 57-66, Vol. 16

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
AUG 23 2003  
TECH CENTER 160012900



AUG 18 2003

PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number		09/868,261
	Filing Date		October 5, 2001
	Confirmation Number		Unknown
	First Named Inventor		John P. McKearn et al.
	Group Art Unit		1614
	Examiner Name		Unknown
	Sheet	9	of
Attorney Docket No.			PHA 4297 (3167/8Z)

RECEIVED  
AUG 23 2003  
TECH CENTER 160012900

128.	FISHER, J.E., et al., Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, An, "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, Endocrinology, 1993, pp. 1411-1413, Vol. 132, No. 3	
129.	FORMENTI, C., et al., Concurrent paclitaxel and radiation in locally advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S12, Abstract 39	
130.	GALARDY, R.E., et al., Inhibition of Angiogenesis by the Matrix Metalloprotease Inhibitor N-[2R-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide, Cancer Research, Sept. 1, 1994, pp. 4715-4718, Vol. 54	
131.	GIANNIS, A., et al., Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy, Angew. Chem. Int. Ed. Engl., 1997, pp 588-590, Vol. 36, No. 6	
132.	GUTTERMAN, J.U., Cytokine Therapeutics: Lessons from interferon $\alpha$ , Proc. Natl. Acad. Sci., USA, Feb. 1994, pp. 1198-1205, Vol. 91	
133.	HANDSCHUMACHER, R.E., et al., Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 712-732, Ch. XV1-2, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers	
134.	IHDE, D.C., M.D., Current Status of Therapy for Small Cell Carcinoma of the Lung, Cancer, Dec. 1, 1984 Supplement, pp. 2722-2728, Vol. 54	
135.	International Search Report for application no. PCT/US99/30692, dated September 1, 2000	
136.	JAYSON, G.C., ET AL., A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer, British Journal of Cancer, 1998, pp. 366-369, Vol. 78(3)	
137.	JOSS, R.A., et al., New agents in non-small cell lung cancer, Cancer Treatment Reviews, 1984, pp. 205-236, Vol.11	
138.	KROWN, S.E., The Role of Interferon in the Therapy of Epidemic Kaposi's Sarcoma, Seminars in Oncology, June, 1987, pp.27-33, Vol. 14, No. 2, Suppl. 3	
139.	LINGEN, M.W., et al., Retinoic Acid and Interferon $\alpha$ Act Synergistically as Antiangiogenic and Antitumor Agents against Human Head and Neck Squamous Cell Carcinoma, Cancer Research, Dec. 1, 1998, pp. 5551-5558, Vol. 58	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUG 18 2003

PTO/SB/08

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown

Sheet	10	of	13	Attorney Docket No.	PHA 4297 (3167/8Z)
-------	----	----	----	---------------------	--------------------

140.	LODE, H.N., et al., Synergy between an antiangiogenic integrin $\alpha$ , antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases, Proc. Nat. Acad. Sci. USA., Feb. 1999, pp. 1591-1596, Vol. 96	
141.	LOKESHWAR, B.L, MMP Inhibition in Prostate Cancer, Annals of the New York Academy of Science, June 1999, pp. 271-289, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
142.	MACKEAN, M.J., et al., A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma, British Journal of Cancer, 1998, pp. 1620-1623, Vol. 78(12)	
143.	MAIONE, T.E., et al., Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides, Science, Jan. 5, 1990, pp. 77-79, Vol. 247	
144.	MAJEWSKI, S., et al., Synergistic Anticancer Action of Retinoids, Vitamin D3 and Cytokines (Interferons and Interleukin-12) as Related to the Antiangiogenic and Antiproliferative Effects, J.Invest.Dermatol., April 1997, Abstract 202, Vol. 108, No. 4	
145.	MONTGOMERY, A.M.P., et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, Proc. Natl. Acad. Sci. USA, Sept. 1994, pp. 8856-8860, Vol. 91	
146.	MOON, R.C., et al., N-(4-Hydroxyphenyl)retinamide, A New Retinoid for Prevention of Breast Cancer in the Rat, Cancer Research, April 1979, pp. 1339-1346, Vol. 39	
147.	MÜLLER, H., Antio-genesis-inhibition and intra-arterial chemotherapy - A new modality treatment for advanced and metastatic pancreatic carcinoma, Eur.J.Cancer 33, 1997, Abstract 215, p. S50, Suppl. 8	
148.	NAITO, K., et al., Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase Inhibitor, Int. J. Cancer, 1994, pp. 730-735, Vol 58	
149.	NERI, A., et al., Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice, Proceedings of the American Association for Cancer Research, Mar. 1998, p. 302, Abstract 2060, Vol. 39	
150.	O'REILLY, M.S., et al., Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell, Jan. 24, 1997, pp. 277-285, Vol. 88	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
AUG 23 2003  
TECH CENTER 160012900



PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown

Sheet	11	of	13	Attorney Docket No.	PHA 4297 (3167/8Z)
-------	----	----	----	---------------------	--------------------

151.	OSAKI, A., et al., A combination therapy with mitomycin-C, etoposide, doxifluridine and medroxyprogesterone acetate as second-line therapy for advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S16, Abstract 56
152.	PFAFF, M., et al., Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by $\alpha 1 \text{Ib} \beta 3$ , $\alpha \text{V} \beta 3$ , and $\alpha 5 \beta 1$ Integrins, The Journal of Biological Chemistry, Aug. 12, 1994, pp. 20233-20238, Vol. 269, No. 32
153.	POWLES, T.J., II.1 Tamoxifen's Oestrogen-like Effects in a Breast Cancer Chemoprevention Trial, European Journal of Cancer, 1998, pp. S17-S18, Vol. 34, Suppl. 4, printed in Great Britain
154.	RAVAUD, A., et al., Subcutaneous Interleukin-2, Interferon Alfa-2a, and Continuous Infusion of Fluorouracil in Metastatic Renal Cell Carcinoma: A Multicenter Phase II Trial, Journal of Clinical Oncology, Aug. 1998, pp. 2728, 2732, Vol. 16, No. 8
155.	ROSENBERG, S.A., et al., Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b, Journal of Clinical Oncology, Mar. 1999, pp. 968-975, Vol. 17, No. 3
156.	RYAN, C.W., et al., A Phase II Trial of Outpatient Subcutaneous GM-CSF, Interleukin-2, and Interferon-Alpha Plus Oral cis-Retinoic Acid in Patients with Metastatic Renal Cell Cancer, J.Invest.Med., 1998, p. 274A, Vol. 46, No. 7
157.	SCHACHTER, J., et al., A Sequential Four-drug Chemotherapy and Biotherapy with Interferon Alpha and GM-CSF - An Innovative Protocol for the Treatment of Metastatic Melanoma, Cancer Biotherapy & Radiopharmaceuticals, 1998, pp. 155-164, Vol. 13, No. 3
158.	SEFTOR, R.E.B., et al., Role of the $\alpha \text{v} \beta 3$ integrin in human melanoma cell invasion, Proc. Natl. Acad. Sci. USA, Mar. 1992, pp. 1557-1561, Vol. 89
159.	SHALINSKY, et al., Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials, Annals of the New York Academy of Science, June 1999, pp. 236-270, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)
160.	SILBER, R., et al., DNA Topoisomerase I Inhibitors, Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 779-782, Ch. XV1-7, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
AUG 23 2003  
TECH CENTER 1600/2900



RECEIVED  
AUG 20 2003  
TECHNICAL CENTER 1600/2500

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/868,261
				Filing Date	October 5, 2001
				Confirmation Number	Unknown
				First Named Inventor	John P. McKearn et al.
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	12	of	13	Attorney Docket No.	PHA 4297 (3167/8Z)

	161.	SOORI, G.S., et al., Phase II Study of Chemo-Biotherapy with Chlorambucil and Alpha Interferon in Patients with Non-Hodgkin's Lymphoma (NHL), Abstract #4032, Blood, 1998, pp. 240b, Vol. 92, No. 10	
	162.	STADLER, W.M., et al., Multicenter Phase II Trial of Interleukin-2, Interferon- $\alpha$ , and 13-cis-Retinoic Acid in Patients With Metastatic Renal-Cell Carcinoma, Journal of Clinical Oncology, May 1998, pp.1820-1825, Vol. 16, No. 5	
	163.	STRAUSS, G.M., et al., Multimodality Treatment of Stage IIIA Non-Small-Cell Lung Carcinoma: A critical Review of the Literature and Strategies for Future Research, Journal of Clinical Oncology, May, 1992, pp. 829-838, Vol. 10, No. 5	
	164.	SUH, N., et al., Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducible Cyclooxygenase (COX-2) in Mouse Macrophages <sup>1</sup> , Cancer Research, Feb. 15, 1998, pp. 717-723, Vol. 58	
	165.	TAKADA, Y., et al., Structures and functions of integrins, Jikken Igaku, 1996, pp. 2317-2322, Vol. 14 (17), English Abstract from SciFinder, Nov. 29, 2001, p. 3	A
	166.	TEICHER, B.A., et al., Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma, Breast Cancer Research and Treatment, 1995, pp. 227-236, Vol. 36	
	167.	TEICHER, B.A., et al., TNP-470/Minocycline/Cytotoxic Therapy: A Systems Approach to Cancer Therapy, European Journal of Cancer, 1996, pp. 2461-2466, Vol. 32A, No. 14	
	168.	THOMAS, C.A., et al., High-Dose Methotrexate (HD-MTX) Monotherapy in Patients with CNS Non-Hodgkin's Lymphoma, Blood, 1998, Abstract #4033, pp. 240b, Vol. 92, No. 10	
	169.	TOLSMAN, S.S., et al., Peptides Derived from Two Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity, The Journal of Cell Biology, 1993, pp. 497-511, Vol. 122	
	170.	TOURANI, J.-M., et al., Outpatient Treatment With Subcutaneous Interleukin-2 and Interferon Alfa Administration in Combination With Fluorouracil in Patients With Metastatic Renal Cell Carcinoma: Results of a Sequential Nonrandomized Phase II Study, Journal of Clinical Oncology, July 1998, pp. 2505-2513, Vol. 16, No. 7	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUG 18 2003

C80

PATO/SB/08

PATENT &amp; TRADEMARK OFFICE

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/868,261
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket No.	PHA 4297 (3167/8Z)

Sheet	13	of	13
-------	----	----	----

RECEIVED  
AUG 2 1 2003  
TECH CENTER 160012900

171.	TUSZYNSKI, G.P., et al., The role of thrombospondin-1 in tumor progression and angiogenesis, Bioessays, 1996, pp. 71-76, Vol. 18, No. 1	
172.	VARNER, J.A., et al., Tumor Angiogenesis and the Role of Vascular Cell Integrin $\alpha v \beta 3$ , Impt. Adv. Onc., 1996, pp. 69-87	
173.	ZUCKER, S., Experimental Models to Identify Antimetastatic Drugs: Are We There Yet?, A Position Paper, Annals of the New York Academy of Science, June 1999, pp. 208-211, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
174.	ZUCKER, S., et al., Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues, Clinical and Experimental Applications, Annals of the New York Academy of Science, June 1999, pp. 212-227, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.